However, current mainstream T2DM treatments—such as insulin and sulfonylureas—are commonly accompanied by weight gain (Chaudhury et al., 2017), making it difficult to meet patients demand for comprehensive metabolic management. This evidence concerns the gene INS and type 2 diabetes mellitus.